다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

GMAB

Genmab AS (GMAB)

Genmab AS

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GMAB

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/14	23:05	Business Wire	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	NASDAQ:GMAB	Genmab AS
2024/05/14	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/03	14:35	Business Wire	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/03/12	02:43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03:50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03:26	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/02	07:04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:GMAB	Genmab AS
2024/03/01	01:47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/29	01:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/28	06:55	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	21:45	Business Wire	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/02/27	02:19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	00:40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/23	06:28	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:GMAB	Genmab AS
2024/02/21	01:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	05:42	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	03:49	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:GMAB	Genmab AS
2024/02/15	02:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/02	20:45	Business Wire	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/02/01	01:17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/23	23:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/09	21:45	Dow Jones News	Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval	NASDAQ:GMAB	Genmab AS
2024/01/09	20:45	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/01/09	20:45	Business Wire	TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/01/03	22:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2023/12/14	01:46	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2023/12/10	02:00	Business Wire	New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
2023/12/10	02:00	PR Newswire (US)	New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS

검색 관련기사 보기:NASDAQ:GMAB

1 2 3 4 5 6 7 8 다음 >>

Leonteq Securities

Societe Generale Effekten

iShares Digital Security...

Vaneck Vectors Junior Go...

Acadia Healthcare

Eaton Vance Limited Dura...

PETRD21 Ex:11,38

ProShares Ultra FTSE Chi...

Zacatecas Silver (PK)

DAXglobal Asia Technolog...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관